Gaestel Matthias, Kotlyarov Alexey, Kracht Michael
Hannover Medical School, Institute of Biochemistry, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
Nat Rev Drug Discov. 2009 Jun;8(6):480-99. doi: 10.1038/nrd2829.
Inflammation is an evolutionarily conserved host reaction that is initiated in response to trauma, tissue damage and infection. It leads to changes in tissue homeostasis and blood flow, immune-cell activation and migration, and secretion of cytokines and mediators in a spatio-temporally coordinated manner. Progress in understanding of the mechanisms of the inflammatory response has identified various protein kinases that act as essential signalling components and therefore represent potential therapeutic targets. This article summarizes advances in the identification and validation of such targets, and discusses key issues for the development of small-molecule kinase inhibitors as a new generation of oral anti-inflammatory drugs, including feedback loops, inhibitor specificity and combination therapy.
炎症是一种进化上保守的宿主反应,它是在对创伤、组织损伤和感染作出反应时启动的。它导致组织稳态和血流发生变化,免疫细胞激活和迁移,并以时空协调的方式分泌细胞因子和介质。对炎症反应机制的理解取得的进展已经确定了各种蛋白激酶,它们作为重要的信号成分发挥作用,因此是潜在的治疗靶点。本文总结了此类靶点的鉴定和验证方面的进展,并讨论了开发小分子激酶抑制剂作为新一代口服抗炎药物的关键问题,包括反馈回路、抑制剂特异性和联合治疗。